Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial
Authors' conclusion
Daily oral elecoglipron demonstrated clinically meaningful weight reductions and a safety and tolerability profile consistent with the GLP-1 receptor agonist class in this phase 2 dose-ranging study, supporting phase 3 investigation in people living with obesity or overweight.
Study context
- Population
- Adults ≥18 years with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with ≥1 weight-related condition, without T2D; centres in Australia, Canada, Germany, Japan, Taiwan, UK, USA; mean age 48.4 years, 73% female, mean BMI 38.2 kg/m²288 completed study
- Participants
- 310 adults
- Comparison
- Oral once-daily elecoglipron vs placebo
- Primary endpoint
- Dual: percent change in bodyweight from baseline and proportion reaching ≥5% weight loss
- Follow-up
- Week 26
Methodological detailsdouble-blind, placebo-controlled, phase 2, dose-ranging, multicentre
- Double-blind
- Placebo-controlled
- Phase 2
- Dose-ranging
- Multicentre
Primary result
As reported in the abstract
Percent change in bodyweight from baseline
5 mg
−2.6
mean · %
75 mg (weekly titration)
−10.5
mean · %
Placebo
−0.6
mean · %
- Estimated proportion reaching ≥5% weight loss at week 26: elecoglipron (range across doses) vs placebo 15.6%
- 40.4-88.8%
Safety
| Outcome | Values |
|---|---|
| Adverse events | Placebo 84% |
- Adverse events — Adverse events across elecoglipron doses (84% [27 of 32] to 98% [48 of 49])
- 84%–98%
Adverse events
- Most common: nausea, constipation, diarrhoea, headache, vomiting
Original publication
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial. Lancet. Published 8 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →